Cross Country Healthcare Details CEO Kevin Clark's Substantial Compensation Package
summarizeSummary
Cross Country Healthcare has detailed the substantial compensation and severance package for its new President and CEO, Kevin C. Clark, in an amended 8-K filing.
check_boxKey Events
-
CEO Compensation Details Disclosed
The company filed an amendment to provide the full compensation arrangements for its new President and CEO, Kevin C. Clark, following his appointment on December 15, 2025.
-
Annual Base Salary Set
Mr. Clark will receive an initial annual base salary of $950,000.
-
Significant Incentive Programs
He is eligible for an Annual Cash Incentive Program (ACIP) bonus with a target of 100% of base salary for 2026 (125% thereafter) and a Long-Term Incentive (LTI) equity award with a target value of 300% of base salary for 2026 (325% thereafter).
-
Generous Severance Provisions
The employment agreement includes substantial severance benefits, such as two years of base salary, two times the average ACIP bonus, two years of COBRA reimbursements, and accelerated vesting of all unvested equity awards if terminated without cause or for good reason.
auto_awesomeAnalysis
Cross Country Healthcare has disclosed the comprehensive compensation package for its new President and CEO, Kevin C. Clark, through an amendment to a previous 8-K filing. This disclosure is very important as it outlines the financial commitment to the company's top executive, which includes a significant base salary, substantial annual cash incentives, and long-term equity awards. The generous severance provisions, including two years of base salary and accelerated equity vesting, are designed to attract and retain high-caliber leadership but also represent a material financial obligation for the company. Investors should consider the implications of this executive compensation structure on the company's overall expenses and shareholder value.
At the time of this filing, CCRN was trading at $8.06 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $264M. The 52-week trading range was $7.43 to $18.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.